Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidofludimus Calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis
NCT03846219Phase 2Active, not recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) (5 cohorts), sponsored by Immunic Therapeutics. Primary endpoint: Cumulative Number of Combined Unique Active (CUA) MRI Lesions at 24 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03846219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846219.